G-Protein Coupled Receptor Targeting(GPCR) Market Attracts Pharma R&D Investments | Abcam plc, Promega Corporation, PerkinElmer Inc, Thermo Fisher Scientific

"G-protein Coupled Receptor (GPCR) Targeting Market is Expected to reach at a high CAGR of 6.40% during the forecast period (2024-2031)." As per DataM intelligence research report

G-Protein Coupled Receptor Targeting Market growth opportunities(2025-2031):

The GPCR targeting market is expanding rapidly as GPCRs remain one of the most validated and druggable protein families in human biology. With over one-third of all approved drugs acting on GPCRs, the demand is rising for selective, potent, and safer therapeutic candidates. Advances in structural biology, cryo-electron microscopy, and AI-powered drug design are accelerating the identification of novel GPCR targets. Growth is also driven by unmet needs in oncology, CNS disorders, and metabolic diseases where GPCR-targeted therapies are showing high efficacy. Biotech collaborations and increasing investments in GPCR-focused pipelines present substantial growth avenues over the next decade.

Download your exclusive sample report today: (corporate email gets priority access): https://www.datamintelligence.com/download-sample/g-protein-coupled-receptor-targeting-market?sp

G-Protein Coupled Receptor Targeting Market: Recent Industry Developments

✅ In July 2025, Pfizer initiated Phase 1 trials for its novel GPCR-targeting compound in metabolic disorders.The drug focuses on GLP-1 receptor modulation to improve insulin sensitivity and appetite control.Early data shows promising tolerability and receptor selectivity.

✅ In June 2025, GPCR Therapeutics Inc. raised $85 million in Series C funding to accelerate pipeline expansion.The biotech firm specializes in dimeric GPCR targeting for oncology and inflammatory diseases.The funding will support IND filings and global research collaborations.

✅ In May 2025, AstraZeneca partnered with Sosei Heptares to co-develop small molecule GPCR agonists.The alliance focuses on neurodegenerative diseases, targeting orphan GPCRs with precision ligands.This marks one of the largest GPCR-focused collaborations in 2025.

✅ In April 2025, Schrödinger Inc. unveiled its AI-powered GPCR modeling platform for drug discovery.The system predicts binding conformations for over 150 GPCR subtypes with atomic-level accuracy.Pharma clients are already applying it in cardiovascular and CNS pipeline projects.

✅ In March 2025, Bristol Myers Squibb expanded its GPCR drug discovery unit with a new Boston research hub.The facility will integrate cryo-EM and AI tools to accelerate ligand identification and optimization.The move reinforces BMS's focus on hard-to-drug GPCR targets in oncology.

G-Protein Coupled Receptor Targeting Market: Technological Advancements

✦ Cryo-EM and X-ray crystallography advancements have enabled high-resolution structural mapping of complex GPCR-ligand interactions.
✦ AI-driven drug discovery platforms are accelerating the screening and optimization of GPCR-targeted compounds with enhanced specificity.
✦ Biased agonism research allows modulation of specific GPCR signaling pathways, improving efficacy while reducing adverse effects.
✦ Label-free screening technologies, such as impedance-based systems, enable real-time analysis of GPCR activation in live cells.
✦ GPCR-targeted biologics like monoclonal antibodies and nanobodies are emerging as alternatives to traditional small-molecule drugs.

G-Protein Coupled Receptor Targeting Market: Drivers

The GPCR targeting market is driven by the growing prevalence of chronic diseases such as neurological disorders, cancer, diabetes, and cardiovascular conditions, where GPCRs are key therapeutic targets. Pharmaceutical and biotech companies are investing heavily in GPCR drug discovery, accelerating the development pipeline. Technological advancements in high-throughput screening, structural biology, and assay platforms are streamlining target identification and drug development. The integration of AI and machine learning enhances predictive modeling and optimizes drug design. Personalized medicine is also gaining traction, enabling GPCR-targeted therapies tailored to specific genetic profiles.

Rising demand for GPCR-targeted treatments in oncology, CNS, and metabolic disorders is fueling innovation and revenue growth. Biologics like nanobody-based GPCR modulators are gaining momentum due to their high specificity and reduced side effects. Rapid pharmaceutical development in Asia-Pacific, particularly China and India, is expanding the market landscape. Academic-industry collaborations and CRO partnerships are accelerating discovery and clinical translation. Regulatory support for precision therapies is improving approval rates and encouraging the launch of next-generation GPCR drugs.

Strategic Players Driving the G-Protein Coupled Receptor Targeting Market Forward:

Abcam plc, Enzo Life Sciences, Inc, Promega Corporation, PerkinElmer Inc, Thermo Fisher Scientific, Eurofins DiscoverX Products, WuXi AppTec (HD Biosciences Co. Ltd), BioInvenu Inc, Danaher Corporation (Molecular Devices LLC) and Merck KGaA.

Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/g-protein-coupled-receptor-targeting-market?sp

Research Methodology:

The global G-Protein Coupled Receptor Targeting Market research report employs a comprehensive dual-source approach, integrating both primary and secondary data collection methods to ensure robust market analysis. Our research framework systematically evaluates multiple industry-influencing variables, including regulatory frameworks and government policies, prevailing market conditions, competitive intensity levels, historical performance data, current market positioning, technological innovations and disruptions, emerging industry developments, cross-sector business impacts, market volatility patterns, growth prospects, potential market barriers, and strategic challenges facing industry participants.

Segment Covered in the G-Protein Coupled Receptor Targeting Market:

➥ By Product: Cell Lines, Detection Kits, Cell Culture Reagents, Ligands
➥ By Application Segment: Cancer Research, CNS Research, Metabolic Research, Cardiovascular Research, Respiratory Research, Inflammation Research, Other Applications
➥ By End-User: cAMP Functional Assays, Calcium Functional Assays, β-Arrestin Functional Assays, Radioligand Binding and GTPγS Functional Assays, Internalization Assays, Trafficking Assays, Other Assays

Regional Analysis for G-Protein Coupled Receptor Targeting Market:

North America leads in GPCR drug discovery and development, backed by strong pharmaceutical R&D funding and a high number of clinical trials. Europe follows closely with increasing academic-industry partnerships and supportive regulatory frameworks. Asia-Pacific is showing notable growth, particularly in China and Japan, where biotech investments and translational research programs are expanding rapidly.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=g-protein-coupled-receptor-targeting-market?sp

Request for 2 Days FREE Trial Access:
https://www.datamintelligence.com/reports-subscription?sp

✅ Competitive Landscape
✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Consumer Behavior & Demand Analysis
✅ Import-Export Data Monitoring
✅ Live Market & Pricing Trends

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.